Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Enters Deal With Bayer, Expands Contract With Johnson & Johnson

Premium

PALO ALTO, Calif.--Incyte Pharmaceuticals, a genomic technologies provider here, announced two agreements with large pharmaceutical firms earlier this month. Incyte will give Bayer access to its LifeTools proprietary bioinformatics software that will support Bayer's work discovering gene targets and the development of new therapeutic agents. Incyte said the LifeTools system will enhance Bayer's ability to track research projects and to share data with team members directly from desktop computers. The agreement includes a subscription to LifeSeq, Incyte's annotated version of the public cDNA sequence databases.

And, in a deal expanding upon a 1996 agreement that gave Johnson & Johnson access to Incyte's LifeSeq human gene sequence and expression database, Incyte has agreed to provide Johnson & Johnson with access to its PathoSeq microbial genome database in exchange for undisclosed annual access fees.

PathoSeq contains genomic information from over 30 bacterial and fungal microorganisms, integrated into Incyte's bioinformatics software. The company is currently designing microarrays containing microbial gene sequences from PathoSeq to assist scientists with the genome-wide analysis of gene expression in microbial organisms. Collaborators have the option to participate in Incyte's microbial microarray program.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.